COMMUNIQUÉS West-GlobeNewswire

Avextra Supports Phase II Clinical Trial in Italy on Cannabis-based medicines for Neurodegenerative Diseases
24/10/2025
First patient enrolled in randomized, placebo-controlled study Bensheim, 24. October 2025 – Neurodegenerative diseases represent one of the biggest challenges of our time. In Germany alone, there are currently around 1. [...]
Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed as its new President
24/10/2025
AMSTERDAM, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Polpharma Group, one of the largest pharmaceutical groups operating across Central and Eastern Europe and Central Asia, announces a planned leadership transition. Effective [...]
Vistin Pharma ASA: Invitation to Q3 2025 conference call
24/10/2025
Oslo, Norway, 24 October 2025 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2025 results on Friday 31st of October 2025. Vistin Pharma will host a conference call for all shareholders and interested [...]
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
24/10/2025
MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a [...]
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
23/10/2025
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
23/10/2025
Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRAS G12D and KRAS G12V cell-derived xenograft (CDX) models BBO-11818’s [...]
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
23/10/2025
SAN CARLOS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025
23/10/2025
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for [...]
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
23/10/2025
New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or “Company”), a publicly-trading technology company majority owned by Faraday Future, today announced a [...]
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
23/10/2025
GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 [...]
Teladoc Health Announces Chief Financial Officer Transition
23/10/2025
Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated Outlook NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual [...]
Treace to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
23/10/2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today [...]
Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
23/10/2025
Beijing, China, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ: PTHL) (the “Company”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related [...]
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
23/10/2025
DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
AVAVA Earns New FDA Clearance for the Treatment of Wrinkles
23/10/2025
The High-Energy Non-Ablative Platform Redefining What’s Possible in Skin Revitalization WALTHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- AVAVA, the powerful non-ablative energy platform powered by Focal Point [...]
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
23/10/2025
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. ( [...]
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
23/10/2025
TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]

Pages